Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy.

Abstract

Congenital mesoblastic nephroma (CMN) is usually cured by surgery. The sensitivity of this tumor to chemotherapy is unknown. The recent description of a t(12;15)(p13;q25) chromosomal translocation in both cellular CMN and congenital infantile fibrosarcoma suggests that these entities have a common pathogenesis, and that cellular CMN might respond to chemotherapy like congenital infantile fibrosarcoma does. The authors describe three patients with recurrent cellular CMN who showed a complete response to chemotherapy. Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN.

• Authors: David M Loeb, D Ashley Hill, Jeffrey S Dome
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) 2002 Aug-Sep Vol. 24 Issue 6 Pg. 478-81 ISSN: 1077-4114 [Print] United States
• PMID: 12218597 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Dactinomycin
• Vincristine
• Doxorubicin

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child, Preschool
• Dactinomycin (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Infant
• Infant, Newborn
• Kidney Neoplasms (congenital, drug therapy, pathology)
• Neoplasm Recurrence, Local (drug therapy)
• Nephroma, Mesoblastic (congenital, drug therapy, pathology)
• Prognosis
• Risk Factors
• Vincristine (administration & dosage)